Scranton gives $100,000 in grants to eight veterans' service organizations
SCRANTON — An idea a decade ago for a memorial to honor the hundreds of Scranton veterans who died in wars resulted five years later in the Scranton Veterans Memorial Park at Scranton High School.
The city this year gave the memorial park a $5,000 grant for ongoing maintenance and replacement of flags.
The memorial park and seven other organizations that serve veterans received city grants totaling $100,000 to help them in various ways, including renovating buildings and providing individual assistance services, Mayor Paige Gebhardt Cognetti said Monday during an event at American Legion Connolly Post 568 in Minooka.
Scranton Mayor Paige Cognetti announces grants awarded to veterans at the American Legion Post 568 in Scranton Monday, May 19, 2025. (SEAN MCKEAG / STAFF PHOTOGRAPHER)
The funding, in the city's 2025 operating budget, continues the city's commitment to local veterans, the mayor said. The $100,000 represents an increase from the $80,000 total awarded in 2023 and $85,000 in 2024.
'As a veteran, I like to see how this program has grown over the last three or four years. Who knows what's going to happen in the next five years?' said Pat Ahern, chairman of Scranton Veterans Memorial Park during the announcement event.
'We have so many different organizations now. It's like planting a tree. It starts off small but eventually it grows,' Ahern said.
Vice commander of the American Legion Post 568 Tom Benson joins other legion members as Scranton Mayor Paige Cognetti announces grants awarded to veterans outside of the legion in Scranton Monday, May 19, 2025. (SEAN MCKEAG / STAFF PHOTOGRAPHER)
The city accepted grant applications through April. The recipients, grant amounts and other representatives of recipient organizations who spoke during the announcement event included:
• Agency for Community EmPOWERment of NEPA (ACE), 123 Wyoming Ave., $5,000 to support the Veterans Rise and Ride program that provides transportation to employment and medical appointments. 'This $5,000 was really lifesaving,' ACE Executive Director Jim Wansacz said. 'Without that grant, we would have had to shut that (ride service) down.'
• American Legion Connolly Post 568, 2929 Birney Ave., $20,000 for upgrades to the community hall to improve energy efficiency and provide ADA-compliant seating. Post Commander Sean O'Shea said the post's membership is older and raising money for building maintenance and modernization is difficult. 'We're very grateful for this' grant.
• Bread Basket of NEPA, 550 Madison Ave., $5,000 for its Veteran Food Security Support Initiative which helps Lackawanna County veterans struggling with food insecurity.
• Fight4Vets, 711 Davis St., $10,000 for a rent assistance program that combats veteran homelessness by providing emergency rent support and additional prevention services.
• Scranton Veterans Memorial Park, located at Scranton High School, 63 Munchak Way, Scranton, $5,000 to purchase flags for each Armed Forces branch and continued maintenance of the site.
• UKAVETS, 237 Railroad Ave., $10,000 for the replacement of outdated facilities.
• Valhalla Veterans Services, 2754 Jackson St., $20,000 to support Valhalla's Hope, which removes financial barriers to mental health counseling and suicide intervention services for local veterans.
• Warrior Strong, 311 Adams Ave., $25,000 to support the Resilient Warriors program, its unique comprehensive health and wellness program.
Warrior Strong President Tom Tice said support from the city allowed his organization to double its offerings and open its studio much more often to veterans and their families.
'We can really tell the community — the veteran community — is using our programs every single day,' Tice said.
American Legion Connolly Post 568, 2929 Birney Ave., Scranton, on Monday, May 19, 2025. (JIM LOCKWOOD / STAFF PHOTO)
*
American Legion Connolly Post 568, 2929 Birney Ave., Scranton, on Monday, May 19, 2025. (JIM LOCKWOOD / STAFF PHOTO)
*
Scranton Mayor Paige Cognetti announces grants awarded to veterans at the American Legion Post 568 in Scranton Monday, May 19, 2025. (SEAN MCKEAG / STAFF PHOTOGRAPHER)
*
Vice commander of the American Legion Post 568 Tom Benson joins other legion members as Scranton Mayor Paige Cognetti announces grants awarded to veterans outside of the legion in Scranton Monday, May 19, 2025. (SEAN MCKEAG / STAFF PHOTOGRAPHER)
*
American Legion Connolly Post 568, 2929 Birney Ave., Scranton, on Monday, May 19, 2025. (JIM LOCKWOOD / STAFF PHOTO)
Show Caption
1 of 4
American Legion Connolly Post 568, 2929 Birney Ave., Scranton, on Monday, May 19, 2025. (JIM LOCKWOOD / STAFF PHOTO)
Expand
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
7 hours ago
- Yahoo
Metsera to Present New Research Highlighting the Breadth and Momentum of its Next-Generation Obesity Portfolio at the 85th Scientific Sessions of the American Diabetes Association®
Four presentations on MET-097i, a fully biased, monthly, ultra-long acting GLP-1 receptor agonist, including two clinical data presentations Additional preclinical presentations on other differentiated portfolio assets, including MET-233i, a monthly, ultra-long acting amylin analog NEW YORK, June 05, 2025 (GLOBE NEWSWIRE) -- Metsera, Inc. (Nasdaq: MTSR), a clinical-stage biopharmaceutical company accelerating the next generation of medicines for obesity and metabolic diseases, will highlight the breadth and momentum of its portfolio of ultra-long acting, scalable, and combinable therapies, including updated clinical and preclinical findings from lead program MET-097i, at the 85th Scientific Sessions of the American Diabetes Association® (ADA). 'We look forward to presenting work spanning our portfolio to the scientific community at this year's ADA meeting,' said Whit Bernard, Chief Executive Officer of Metsera. 'Our presentations, including clinical data from the completed Phase 1/2 trial of MET-097i and preclinical findings for our other programs, showcase the breadth of our next-generation approaches to address the need for scalable and differentiated treatments for overweight and obesity.' Presentation Highlights MET-097i: A fully biased, ultra-long acting GLP-1 receptor agonist MET-097i is Metsera's fully biased, monthly, ultra-long acting GLP-1 receptor agonist. Metsera will present clinical data from MET-097i's Phase 1/2 clinical trial in two presentations, including change in body weight and tolerability data after twelve weekly doses and after a single candidate monthly dose. MET-233i: An ultra-long acting amylin analog MET-233i is Metsera's monthly, ultra-long acting amylin analog. Metsera will present preclinical data, including detailed pharmacokinetic and change in body weight data. Presentation Details: MET-097i: A fully biased ultra-long acting GLP-1 receptor agonist Clinical data Title: A Twelve-Week Trial of MET-097—A Potent and Ultra-Long-Acting GLP-1 Receptor Agonist (788-P)Session: Sunday General Poster SessionPresenter: Robert Stoekenbroek, M.D., Ph.D., Head of Portfolio Strategy at Metsera Time/Date: Sunday, June 22; 12:30-1:30pm CDTLocation: Poster Hall (Hall F1), 122 Title: Safety, Tolerability, PK, and Efficacy of MET-097—A Next-Generation Nutrient-Stimulated Hormone Peptide Analog for Chronic Weight Management (753-P)Session: Sunday General Poster SessionPresenter: Steve Marso, M.D., Chief Medical Officer at MetseraTime/Date: Sunday, June 22; 12:30-1:30pm CDTLocation: Poster Hall (Hall F1), 088 Preclinical data Title: MET-097: Preclinical Characterization of a Potent and Ultra-Long-Acting GLP-1 Receptor Agonist (794-P)Session: Sunday General Poster SessionPresenter: Charlotte Hinds, Ph.D., Senior Director, Research & Development at MetseraTime/Date: Sunday, June 22; 12:30-1:30pm CDTLocation: Poster Hall (Hall F1), 128 Title: Cellular Characterisation of Signalling and Receptor Trafficking Induced by MET-097, a G Protein-Biased GLP-1R Agonist (799-P)Session: Sunday General Poster SessionPresenter: Billy Peter Baxter, Ph.D., Imperial College LondonTime/Date: Sunday, June 22; 12:30-1:30pm CDTLocation: Poster Hall (Hall F1), 133 MET-233: An ultra-long acting amylin analog Preclinical data Title: MET-233 Is an Ultra-Long-Acting Amylin Receptor Agonist (894-P)Session: Sunday General Poster SessionPresenter: James S Minnion, Ph.D., Vice President, Research & Development at MetseraTime/Date: Sunday, June 22; 12:30-1:30pm CDTLocation: Poster Hall (Hall F1), 190 Pipeline programs Preclinical data Title: Therapeutic NuSH Cocktails—Coadministration of Ultra-Long-Acting GLP-1, GIP, Glucagon, and Amylin Peptide Analogs Induce Profound Weight Loss in DIO Mice (765-P)Session: Sunday General Poster SessionPresenter: Robert Hansford, Ph.D., Preclinical Research Scientist at MetseraTime/Date: Sunday, June 22; 12:30-1:30pm CDTLocation: Poster Hall (Hall F1), 100 Health Economics and Outcomes Research Title: Titration to Maintenance Doses of GLP-1R Agonists for Overweight and Obesity Is Suboptimal for Majority of Patients—Evidence from a Real-World Claims Dataset (758-P)Session: Sunday General Poster SessionPresenter: Shannon Armstrong, Vice President, Global Value and Access at MetseraTime/Date: Sunday, June 22; 12:30-1:30pm CDTLocation: Poster Hall (Hall F1), 093 For more information about Metsera's presence at ADA, visit About Metsera Metsera is a clinical-stage biopharmaceutical company accelerating the next generation of medicines for obesity and metabolic diseases. Metsera is advancing a broad portfolio of oral and injectable incretin, non-incretin and combination therapies with potential best-in-class profiles to address multiple therapeutic targets and meet the future needs of a rapidly evolving weight loss treatment landscape. Metsera was founded in 2022 and is based in New York City. For more information, please visit us at and follow us on LinkedIn and X. Metsera may use its website as a distribution channel of material information about the Company. Financial and other important information regarding the Company is routinely posted on and accessible through the Investors & News section of its website at In addition, you may sign up to automatically receive email alerts and other information about the Company by using the 'Email Alerts' option on the Investors & Media page and submitting your email address. Forward-Looking Statements This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the "Act"). Examples of such statements include, but are not limited to, statements relating to Metsera's expectations regarding participation and presentations at the 85th Scientific Sessions of the American Diabetes Association® (ADA), its research and development activities, and statements regarding the efficacy, safety and potential regulatory progress of its investigational candidates. Such statements are based on management's current expectations, but actual results may differ materially due to various risks and uncertainties, including, but not limited to the risks related to Metsera's business outlined in Metsera's filings with the Securities and Exchange Commission, including in the 'Risk Factors' section of its Annual Report on Form 10-K for the year ended December 31, 2024. Forward-looking statements are not guarantees of future performance, and Metsera's actual results of operations, financial condition and liquidity, and the development of the industry in which it operates, may differ materially from the forward-looking statements contained in this press release. Any forward-looking statements that Metsera makes in this press release speak only as of the date of this press release. Metsera assumes no obligation to update its forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release. Contact:Jono EmmettMetseramedia@ while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Yahoo
8 hours ago
- Yahoo
3 Hidden Catalysts That Could Send XRP to $5 by 2027
Companies are increasingly holding XRP in their corporate treasuries. More regulation is starting to bring XRP into mainstream payments. A potential ETF approval could accelerate institutional inflows. 10 stocks we like better than XRP › XRP (CRYPTO: XRP) trades for about $2.15 today. Yet a trio of developments, including corporate treasury adoption, new regulated onramps and payment rails, and the potential approval of exchange-traded funds (ETFs) could shift the token's supply-demand balance enough to put $5 within reach by 2027. Each of these catalysts are real, but they are not guaranteed to land on schedule in terms of their price impact. Still, the combined effect could be stronger than the sum of the parts. So investors who wrote XRP off after its courtroom troubles may want to revisit the math. The idea that companies are buying and holding XRP is gaining traction among corporate strategists, and that dynamic has the potential to boost XRP prices over time. VivoPower International (NASDAQ: VVPR) just earmarked $121 million for an XRP-centric digital-asset corporate treasury program, making it the first public company in the world to do so. That single move locks up a large amount of XRP, which is supply that will likely sit idle for years. In other words, every corporate balance sheet allocation forces new buyers to compete for a shrinking pool of coins. If even a handful of companies imitate VivoPower, and there probably will be, the float (XRP available for public trading) tightens. Treasury managers crave liquid, low-friction assets, and XRP's sub-penny transfer costs check that box. Watch for more adopters by the end of the year. Even if the business logic behind holding a volatile asset like XRP on the balance sheet is sketchy, it could still spark a larger trend that benefits holders. Regulated financial channels matter for XRP's adoption among institutional investors as well as its pricing. MiCA (Markets in Crypto-Assets) is the E.U.'s comprehensive crypto regulation package that sets standards for stablecoins, tokenized assets, and service providers, offering a consistent legal framework for businesses that want to deploy XRP at scale. And when crypto products comply with those standards, they have a much higher chance of attracting institutional capital inflows. In that vein, on May 22 Schuman Financial launched the first MiCA-compliant euro stablecoin on the XRP Ledger. The token is fully backed by euros in E.U.-regulated accounts, giving institutional desks a plug-and-play payment settlement solution that did not exist last quarter. Therefore, euro-denominated funds can shift their capital on-chain without tripping any regulatory alarms. Ripple, the company that issues XRP, also just secured a Dubai Financial Services Authority license and immediately onboarded a bank plus a payments fintech called Mamo. The U.A.E. is a global financial hub that annually clears trillions in cross-border payment flows each year, so plugging XRP into that plumbing broadens real-world throughput while increasing demand for the coin. On-chain metrics respond quickly. XRPL daily transactions exceeded 900,000 in late May as new decentralized finance (DeFi) venues and payout corridors went live, and in the long view of things, the party's probably just getting started. Volume spikes can fade, yet they hint that liquidity on the chain is scaling alongside compliance tooling. And that could be another draw for bigger players that need the liquidity for their commensurately bigger transactions. An ETF offering investors exposure to XRP is very likely to be approved before the end of 2025. The prediction market Polymarket stakes it at roughly 90% for a positive decision by the Securities and Exchange Commission this year. An ETF would hand traditional brokers a turnkey wrapper, unlocking retirement-plan and wealth-manager capital that can't directly hold crypto. Furthermore, ETF issuers will have to buy crypto to back their initial offerings to investors. And as capital flows into the ETFs, issuers must scale up their purchases. Regulatory timing is the wild card. The SEC could delay, or green-light another asset first. If an asset that the market views as being smaller-time than XRP gets an ETF approval first, it would be seen as a bearish sign for the asset even though it won't change anything about the investment thesis for buying it. And if broader crypto sentiment sours, demand could freeze until conditions improve. The bullish script discussed above assumes: More than one corporate treasury allocation Sustained growth in markets outside the U.S. At least one U.S.-listed or E.U.-listed XRP ETF by late 2025 If any of these prospects don't pan out, the path to $5 will take longer at best. There could even be some sharp downside in store in the short or medium term. Some other caveats. Competing payment networks could siphon flows. Liquidity shocks across crypto could push XRP toward forced selling before catalysts mature. That means you should lock in for the long term if you decide to invest in XRP; be ready to hold for a few years or more. Still, the narrative around XRP has evolved from defensive lawsuits to offensive integrations. Each catalyst chips away at the old bear case and adds a fresh source of non-speculative demand. For cautious investors, the blend of improving fundamentals and asymmetric upside looks a lot harder to ignore than it did a year ago. Before you buy stock in XRP, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and XRP wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $656,825!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $865,550!* Now, it's worth noting Stock Advisor's total average return is 994% — a market-crushing outperformance compared to 172% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 2, 2025 Alex Carchidi has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends XRP. The Motley Fool has a disclosure policy. 3 Hidden Catalysts That Could Send XRP to $5 by 2027 was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
9 hours ago
- Yahoo
Metsera to Present New Research Highlighting the Breadth and Momentum of its Next-Generation Obesity Portfolio at the 85th Scientific Sessions of the American Diabetes Association®
Four presentations on MET-097i, a fully biased, monthly, ultra-long acting GLP-1 receptor agonist, including two clinical data presentations Additional preclinical presentations on other differentiated portfolio assets, including MET-233i, a monthly, ultra-long acting amylin analog NEW YORK, June 05, 2025 (GLOBE NEWSWIRE) -- Metsera, Inc. (Nasdaq: MTSR), a clinical-stage biopharmaceutical company accelerating the next generation of medicines for obesity and metabolic diseases, will highlight the breadth and momentum of its portfolio of ultra-long acting, scalable, and combinable therapies, including updated clinical and preclinical findings from lead program MET-097i, at the 85th Scientific Sessions of the American Diabetes Association® (ADA). 'We look forward to presenting work spanning our portfolio to the scientific community at this year's ADA meeting,' said Whit Bernard, Chief Executive Officer of Metsera. 'Our presentations, including clinical data from the completed Phase 1/2 trial of MET-097i and preclinical findings for our other programs, showcase the breadth of our next-generation approaches to address the need for scalable and differentiated treatments for overweight and obesity.' Presentation Highlights MET-097i: A fully biased, ultra-long acting GLP-1 receptor agonist MET-097i is Metsera's fully biased, monthly, ultra-long acting GLP-1 receptor agonist. Metsera will present clinical data from MET-097i's Phase 1/2 clinical trial in two presentations, including change in body weight and tolerability data after twelve weekly doses and after a single candidate monthly dose. MET-233i: An ultra-long acting amylin analog MET-233i is Metsera's monthly, ultra-long acting amylin analog. Metsera will present preclinical data, including detailed pharmacokinetic and change in body weight data. Presentation Details: MET-097i: A fully biased ultra-long acting GLP-1 receptor agonist Clinical data Title: A Twelve-Week Trial of MET-097—A Potent and Ultra-Long-Acting GLP-1 Receptor Agonist (788-P)Session: Sunday General Poster SessionPresenter: Robert Stoekenbroek, M.D., Ph.D., Head of Portfolio Strategy at Metsera Time/Date: Sunday, June 22; 12:30-1:30pm CDTLocation: Poster Hall (Hall F1), 122 Title: Safety, Tolerability, PK, and Efficacy of MET-097—A Next-Generation Nutrient-Stimulated Hormone Peptide Analog for Chronic Weight Management (753-P)Session: Sunday General Poster SessionPresenter: Steve Marso, M.D., Chief Medical Officer at MetseraTime/Date: Sunday, June 22; 12:30-1:30pm CDTLocation: Poster Hall (Hall F1), 088 Preclinical data Title: MET-097: Preclinical Characterization of a Potent and Ultra-Long-Acting GLP-1 Receptor Agonist (794-P)Session: Sunday General Poster SessionPresenter: Charlotte Hinds, Ph.D., Senior Director, Research & Development at MetseraTime/Date: Sunday, June 22; 12:30-1:30pm CDTLocation: Poster Hall (Hall F1), 128 Title: Cellular Characterisation of Signalling and Receptor Trafficking Induced by MET-097, a G Protein-Biased GLP-1R Agonist (799-P)Session: Sunday General Poster SessionPresenter: Billy Peter Baxter, Ph.D., Imperial College LondonTime/Date: Sunday, June 22; 12:30-1:30pm CDTLocation: Poster Hall (Hall F1), 133 MET-233: An ultra-long acting amylin analog Preclinical data Title: MET-233 Is an Ultra-Long-Acting Amylin Receptor Agonist (894-P)Session: Sunday General Poster SessionPresenter: James S Minnion, Ph.D., Vice President, Research & Development at MetseraTime/Date: Sunday, June 22; 12:30-1:30pm CDTLocation: Poster Hall (Hall F1), 190 Pipeline programs Preclinical data Title: Therapeutic NuSH Cocktails—Coadministration of Ultra-Long-Acting GLP-1, GIP, Glucagon, and Amylin Peptide Analogs Induce Profound Weight Loss in DIO Mice (765-P)Session: Sunday General Poster SessionPresenter: Robert Hansford, Ph.D., Preclinical Research Scientist at MetseraTime/Date: Sunday, June 22; 12:30-1:30pm CDTLocation: Poster Hall (Hall F1), 100 Health Economics and Outcomes Research Title: Titration to Maintenance Doses of GLP-1R Agonists for Overweight and Obesity Is Suboptimal for Majority of Patients—Evidence from a Real-World Claims Dataset (758-P)Session: Sunday General Poster SessionPresenter: Shannon Armstrong, Vice President, Global Value and Access at MetseraTime/Date: Sunday, June 22; 12:30-1:30pm CDTLocation: Poster Hall (Hall F1), 093 For more information about Metsera's presence at ADA, visit About Metsera Metsera is a clinical-stage biopharmaceutical company accelerating the next generation of medicines for obesity and metabolic diseases. Metsera is advancing a broad portfolio of oral and injectable incretin, non-incretin and combination therapies with potential best-in-class profiles to address multiple therapeutic targets and meet the future needs of a rapidly evolving weight loss treatment landscape. Metsera was founded in 2022 and is based in New York City. For more information, please visit us at and follow us on LinkedIn and X. Metsera may use its website as a distribution channel of material information about the Company. Financial and other important information regarding the Company is routinely posted on and accessible through the Investors & News section of its website at In addition, you may sign up to automatically receive email alerts and other information about the Company by using the 'Email Alerts' option on the Investors & Media page and submitting your email address. Forward-Looking Statements This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the "Act"). Examples of such statements include, but are not limited to, statements relating to Metsera's expectations regarding participation and presentations at the 85th Scientific Sessions of the American Diabetes Association® (ADA), its research and development activities, and statements regarding the efficacy, safety and potential regulatory progress of its investigational candidates. Such statements are based on management's current expectations, but actual results may differ materially due to various risks and uncertainties, including, but not limited to the risks related to Metsera's business outlined in Metsera's filings with the Securities and Exchange Commission, including in the 'Risk Factors' section of its Annual Report on Form 10-K for the year ended December 31, 2024. Forward-looking statements are not guarantees of future performance, and Metsera's actual results of operations, financial condition and liquidity, and the development of the industry in which it operates, may differ materially from the forward-looking statements contained in this press release. Any forward-looking statements that Metsera makes in this press release speak only as of the date of this press release. Metsera assumes no obligation to update its forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release. Contact:Jono EmmettMetseramedia@
